Charles River Laboratories | CRL - Operating Profit


Charles River Laboratories reported $119.89M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Agilent USD 399M 46M Mar/2026
Align Technology USD 191.32M 13.27M Jun/2026
Bio-Rad Laboratories USD 72.6M 38.5M Jun/2026
Bruker USD 69.6M 59.4M Jun/2026
Cardinal Health USD 814M 47M Jun/2026
Charles River Laboratories USD 119.89M 9K Jun/2026
Cigna USD 2.76B 204M Mar/2026
Concord Medical Services Hldg CNY -94.68M 49.97M Dec/2025
CVS Health USD 6.73B 2.05B Jun/2026
Danaher USD 1.13B 217M Jun/2026
Dentsply International USD 84M 52M Jun/2026
Elevance Health USD 2.3B 8.11B Jun/2026
Humana USD 1.36B 394M Jun/2026
Illumina USD 260M 21M Jun/2026
Incyte USD 700.4M 376.22M Jun/2026
Intrexon USD -60.84M 26.62M Jun/2024
IQVIA Holdings USD 2.6B 2.03B Jun/2026
Laboratory Of America USD 456.7M 46.6M Jun/2026
Lakefront Biotherapeutics EUR -43.51M 20.19M Jun/2026
Lonza CHF 673M 243M Jun/2025
McKesson USD 1.42B 415M Jun/2026
Merck EUR 1.1B 51M Jun/2026
Mettler Toledo International USD 287.55M 53.61M Jun/2026
Novartis USD 4.75B 515M Jun/2026
Pfizer USD 667M 4.32B Jun/2026
Quest Diagnostics USD 459M 60M Jun/2026
Revvity USD 126.14M 43.36M Jun/2026
Thermo Fisher Scientific USD 2.18B 273M Jun/2026
United Therapeutics USD 330.8M 5M Jun/2026
UnitedHealth USD 7.99B 1.05B Jun/2026
Veradigm USD -45.47M 70.47M Dec/2022
Waters USD -86M 234M Jun/2026
West Pharmaceutical Services USD 179.1M 2M Jun/2026